# CaniCatiCare to Offer 24-Hour Canine Cancer Mutation Test to US Veterinary Clinics in 2027

> CaniCatiCare's CaniCancer PCR test returns canine tumor mutation results in 24 hours and costs about 80% less than NGS, with US samples accepted in 2027.

- Published: 2026-11-14T14:38:44+00:00
- Section: Product Launches
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-14/canicaticare-canine-cancer-test-us
- Source: [FinancialContent Business Page](https://www.financialcontent.com/article/getnews-2026-11-14-canicaticare-brings-24-hour-canine-cancer-mutation-test-to-us-veterinary-clinics)

## Key takeaways

- CaniCancer screens 23 hotspot mutations across seven cancer-related genes in a single multiplex PCR test.
- The test costs about 80% less than NGS-based testing and returns results within 24 hours of sample receipt.
- CaniCatiCare plans to begin accepting US samples in 2027 and is pursuing partnerships with veterinary hospital networks and diagnostic laboratories.

CaniCatiCare is bringing CaniCancer, its PCR-based tumor mutation test for dogs, to the U.S. Market, with plans to begin accepting U.S. Samples in 2027. The South Korean veterinary precision oncology company unveiled the test at TechCrunch Disrupt 2026, according to the [FinancialContent Business Page](https://www.financialcontent.com/article/getnews-2026-11-14-canicaticare-brings-24-hour-canine-cancer-mutation-test-to-us-veterinary-clinics).

## How the CaniCancer Test Works

CaniCancer uses multiplex PCR to screen for 23 hotspot mutations across seven cancer-related genes in a single test. It works with fine-needle aspirate, tissue and urine samples, and each report includes targeted therapy recommendations such as PI3K, KRAS and c-Kit inhibitors. The company estimates the test costs about 80% less than NGS-based testing.

CaniCatiCare says CaniCancer delivers actionable genetic results within 24 hours of sample receipt. Veterinary oncology testing still relies mostly on next-generation sequencing, which typically takes two to four weeks, a delay the company says can mean missing the best treatment window for aggressive cancers like osteosarcoma.

"Precision oncology in humans works in two steps: a rapid PCR test first, followed by comprehensive sequencing," said Jaewoo Hong, DVM, PhD, founder and CEO of CaniCatiCare. "Veterinary medicine never had that first step. Dogs with aggressive tumors can't wait a month for results. CaniCancer gives veterinarians answers they can act on the next day."

Since launching in South Korea in 2025, CaniCancer has been adopted by more than 100 veterinary hospitals and used in over 400 clinical cases. More than 90% of owners whose dogs were diagnosed with solid tumors chose molecular testing, according to the company. In Hong Kong, CaniCatiCare signed a three-year supply agreement with Jacobson Pharma worth approximately $700,000, opening access to about 250 local veterinary clinics.

In the U.S., CaniCatiCare is pursuing partnerships with veterinary hospital networks and diagnostic laboratories. The company also offers CaniCancer-Free, a liquid biopsy test launched in August 2025 that detects tumor-derived DNA mutations at levels as low as 0.001% from a blood draw, which veterinarians can use to track treatment response, recurrence and metastasis. More information is available on [CaniCatiCare's website](https://ccc.pet).

## CatiCancer and the 2027 Timeline

CaniCatiCare is developing CatiCancer, a test for cats, with commercialization targeted for 2027. The company plans to begin accepting U.S. Samples for CaniCancer in 2027 as well. CaniCatiCare was founded in 2024 and is headquartered in Daegu, South Korea.

## Companies in this story

- CaniCatiCare · website: https://ccc.pet

---
News for Agent · https://newsforagent.com/llms.txt